Immune cell therapy for advanced lung cancer that has returned
Part of Cancer, Lungs & breathing clinical trials.
This trial tests an investigational cell therapy called Trop2 CAR-NK for people with advanced non-small cell lung cancer that has come back after standard treatments. The therapy uses your own immune cells (natural killer cells) that are specially trained to find and attack cancer cells that carry the Trop2 protein. This may help shrink tumors or slow the cancer's growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 to 79 years old.
- You must have stage IIIB or IV non-small cell lung cancer that has come back or not responded to previous treatment.
- Your tumor must show a certain level of the Trop2 protein (at least 50% weak positive).
- If you don't have a driver gene change, you must have already tried immunotherapy combined with chemotherapy and it stopped working.
- If you have an EGFR gene change, you must have already tried a TKI targeted therapy pill and it stopped working.
- You must be in fairly good health overall, with your heart, liver, and kidneys working well enough.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new type of cell therapy using your own immune cells (NK cells) that are specially engineered to attack cancer cells that have a protein called TROP2. It is for people with advanced solid tumors that have not responded to standard treatments.
This study tests a new type of immune cell therapy (CAR-NK cells) designed to recognize and attack lung cancer cells that have spread or stopped responding to standard treatments. The goal is to see if this approach can shrink tumors and help patients live longer.
This trial tests an experimental immune cell therapy (CAR-NK cells) that targets two to three specific markers on your lung cancer cells. It may be an option if your cancer has stopped responding to standard treatments and if tests show your tumor carries those markers.
This study tests a new type of CAR-T cell therapy that targets a protein called Trop2 found on some head and neck cancer cells. It's for people who have tried standard treatments and need a new option.
This study tests a new immune cell treatment called EB-NK-301, which are lab-modified natural killer cells designed to attack cancer cells that have a protein called TROP2. The trial is for people with advanced solid tumors (cancers that have spread) whose cancer has stopped responding to standard treatments.
This trial tests a new combination therapy using your own immune cells (CAR-T and CAR-DC) that are specially trained to attack a protein called EphA2 found on your lung cancer cells. It is for people with advanced non-small cell lung cancer whose cancer has continued to grow after other treatments.
Hear when a new Non-Small Cell Lung Cancer NSCLC trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.